Please provide your email address to receive an email when new articles are posted on . Apremilast led to better clinical outcomes in early oligoarticular PsA vs. placebo at 16 weeks. Safety was ...

WASHINGTON — In the phase 3 PALACE-1 trial, the investigational agent apremilast led to significant improvement in the signs and symptoms of psoriatic arthritis (PsA) in patients who failed to respond ...

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

SAN FRANCISCO, CA—Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast at 20mg and 30mg twice-daily doses continues to demonstrate “sustained and ...

The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet’s syndrome. In a phase 2 trial involving patients with Behçet’s syndrome, apremilast ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Apremilast is superior to placebo regarding joint response and disease control in patients with ...

Pediatric patients with plaque psoriasis receiving apremilast vs placebo experienced significantly greater improvements in global disease activity and skin involvement. Treatment with apremilast was ...

Credit: Getty Images. The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 ADVANCE trial. The Food and Drug Administration (FDA) has accepted for review the ...

As per IQVIATM sales data covering the 12-month period up to August 2023, the market for Otezla® tablets in these dosage forms achieved annual sales of around $3.7 billion. Mumbai: Glenmark ...

Learn everything you need to know about Apremilast-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Researchers conducted a multicenter observational study across three major US academic medical centers with registries of patients with rheumatic immune-related adverse events to assess the ...

Reviewers report that the dossiers submitted regarding the use of Apremilast for psoriasis contained neither data from studies of direct comparisons nor indirect comparisons. The manufacturer itself ...